Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

9 Meters Biopharma, Inc. - Common Stock (NQ: NMTR )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 9 Meters Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
9 Meters Biopharma to Participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) Congress
Via ACCESSWIRE
9 Meters Biopharma to Participate in the Citi 17th Annual BioPharma Conference
Via ACCESSWIRE
9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022
Via ACCESSWIRE
Around $2 Million Bet On This Stock? 4 Penny Stocks Insiders are Buying
The US economy added 372,000 payrolls in June, following a revised 384,000 growth in May. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're diving into all of the latest stock news on Monday with our breakdown of the biggest pre-market stock movers for today! 
Via InvestorPlace
Why Is Twitter Down By More Than 5%? 22 Stocks Moving In Monday's Pre-Market Session
Gainers Inpixon (NASDAQ: INPX) rose 25.8% to $0.2305 in pre-market trading after gaining more than 22% on Friday. 
Via Benzinga
9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022
RALEIGH, NC / ACCESSWIRE / July 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced... 
From 9 Meters Biopharma
Via AccessWire
Exposures Product Safety
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
Initial Draw of $20 Million to Support Funding Phase 3 Development of Vurolenatide in Short Bowel Syndrome 
From 9 Meters Biopharma
Via AccessWire
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today... 
From 9 Meters Biopharma
Via AccessWire
Exposures Product Safety
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning! It's time to start off another busy day of trading with a look at the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
Mosaic Tumbles Around 10%, Here's 71 Biggest Movers From Yesterday
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown... 
Via Benzinga
Why Are 9 Meters Biopharma Shares Plunging Today?
9 Meters Biopharma Inc (NASDAQ: NMTR) completed a pre-specified interim analysis for the Phase 3 study of larazotide for patients with celiac disease who continue to experience gastrointestinal... 
Via Benzinga
67 Biggest Movers From Yesterday
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital. 
Via Benzinga
9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
RALEIGH, NC / ACCESSWIRE / June 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today... 
From 9 Meters Biopharma
Via AccessWire
Exposures Product Safety
9 Meters Biopharma to Participate in the 2022 BIO International Convention
RALEIGH, NC / ACCESSWIRE / June 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,... 
From 9 Meters Biopharma
Via AccessWire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
9 Meters Biopharma to Exhibit at Digestive Disease Week 2022
RALEIGH, NC / ACCESSWIRE / May 19, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced... 
From 9 Meters Biopharma
Via AccessWire
9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Use of Larazotide in Idiopathic Pulmonary Fibrosis
RALEIGH, NC / ACCESSWIRE / May 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced... 
From 9 Meters Biopharma
Via AccessWire
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022
- On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in June - Cash balance as of March 31, 2022, of $37.2 million is expected to... 
From 9 Meters Biopharma
Via AccessWire
Exposures Product Safety
9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From 9 Meters Biopharma
Via AccessWire
9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac Disease
RALEIGH, NC and SANTA ROSA, CA / ACCESSWIRE / April 20, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating... 
From 9 Meters Biopharma
Via AccessWire
9 Meters Biopharma Announces Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious Metabolic Conditions
RALEIGH, NC / ACCESSWIRE / April 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,... 
From 9 Meters Biopharma
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 236 companies hit new 52-week lows. 
Via Benzinga
Recap: 9 Meters Biopharma Q4 Earnings
9 Meters Biopharma (NASDAQ:NMTR) reported its Q4 earnings results on Wednesday, March 23, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021
RALEIGH, NC / ACCESSWIRE / March 23, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today... 
From 9 Meters Biopharma
Via AccessWire
9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference
RALEIGH, NC / ACCESSWIRE / March 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,... 
From 9 Meters Biopharma
Via AccessWire
9 Meters Biopharma to Present at the Oppenheimer 32nd Annual Healthcare Conference
RALEIGH, NC / ACCESSWIRE / March 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,... 
From 9 Meters Biopharma
Via AccessWire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS